Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Resting heart rate tied to hypertension, heart failure

16 Apr 2018

Results of a recent meta-analysis have shown a linear positive relationship between resting heart rate and the incidence of hypertension and heart failure.

There were 13 cohort studies for hypertension and 17 for heart failure included in this study. The respective risk for each disease increased by 11 percent (relative risk [RR], 1.11; 95 percent CI, 1.07–1.15) and 19 percent (RR, 1.19; 1.13–1.25) for each 10 beats-per-minute increment in resting heart rate.

Most subgroup analyses, except for gender subgroups, showed a consistent association between resting heart rate and hypertension or heart failure, with no significant relationship seen in the women subgroup. Furthermore, there was no evidence supporting a nonlinear association of elevated resting heart rate with hypertension and heart failure risk.

The investigators performed a dose-response meta-analysis of studies focusing on risks associated with resting heart rate and hypertension or heart failure. PubMed, Embase, CNKI and WanFang databases were searched for articles published before 15 June 2017.

RRs and 95 percent CIs were pooled using a random-effects model. Restricted cubic spline analysis was conducted to model the resting heart rate-hypertension and heart failure risk association.

In a previous meta-analysis, results showed that higher resting heart rate was independently associated with increased risks of all-cause and cardiovascular mortality, indicating that resting heart rate is a predictor of all-cause and cardiovascular death in the general population. [CMAJ 2016;188:E53-63]

Another study found that higher resting heart rate correlated with both cardiovascular and noncardiovascular mortality. The findings suggest that resting heart rate may be a marker of overall well-being rather than a marker of cardiovascular health. [Am J Cardiol 2017;119:1003-1007]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.